The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 68.00
Bid: 67.00
Ask: 68.60
Change: -3.60 (-5.03%)
Spread: 1.60 (2.388%)
Open: 69.00
High: 69.00
Low: 67.20
Prev. Close: 71.60
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Novacyt donates 1 million COVID-19 tests to UNICEF

4 May 2021 07:00

RNS Number : 3321X
Novacyt S.A.
04 May 2021
 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Novacyt to support UNICEF with donation of one million COVID-19 tests

 

Donation supports testing efforts to help ensure continued access to essential services for children and their families

 

Paris, France and Camberley, UK - 4 May 2021 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT; "Novacyt"), an international clinical diagnostics company, will donate one million COVID-19 polymerase chain reaction (PCR) tests to UNICEF to help contain the spread of the virus through testing.  

 

All over the world, the COVID-19 pandemic has upended the lives of children and their families. During this time, UNICEF has provided support to the most vulnerable children, working to safeguard their access to education, nutrition and essential health services. At the same time, UNICEF acts as a key partner and lead procurer for the Access to COVID-19 Tools Accelerator (ACT-A), a global collaboration to speed up the development, production and equitable access to COVID-19 tests, treatments and vaccines. 

 

By supporting ACT-A, UNICEF aims to help combat the COVID-19 pandemic, potentially save the lives of frontline workers and high-risk populations, make health systems more resilient and ultimately, help ensure that children in low- and middle-income countries survive and thrive.

 

As the world accelerates vaccination efforts against COVID-19, testing remains an important part of global efforts to contain the virus. Novacyt's donation will help UNICEF work with governments to fill gaps in COVID-19 testing capacities. This, in turn, will help to ensure children and their families continue to have access to essential services and care.

 

Novacyt will send the test kits to countries where there is both the need and infrastructure to perform PCR testing. The first four countries whose Ministries of Health have expressed interest and capacity to receive the test kits are Nigeria, Palestine, Maldives, and South Sudan.

 

Graham Mullis, Chief Executive Officer of Novacyt, commented:

"We are proud to support UNICEF and the incredible initiatives it has in place to protect children around the world during the pandemic. There remains a need to contain the spread of COVID-19, not just in high-income countries but on a global scale. Novacyt is committed to playing our part in fighting the pandemic by delivering reliable testing for the virus where it is most needed. We are delighted to be working with UNICEF to support low- and middle-income countries in their response to COVID-19, which will in turn enable access to vital services for children affected by one of the largest ever humanitarian crises. Finally, I am proud of the Novacyt team, as without their dedication and focus the Company would not be in the position it is today, allowing us to support global organisations like UNICEF."

 

Clarence Jaccard-Briat, General Director at UNICEF France, added:

"We are grateful for the contribution Novacyt is providing to UNICEF's role in COVID-19 testing. Our efforts to fight the pandemic won't stop until every child and every family is safe and in good health. Through ACT-A and the COVAX Facility, UNICEF, along with partners, is on a historic mission to vaccinate the world. We invite other partners to join us and support us in this race to end COVID-19. Because no one is safe until everyone is safe."

 

- End -

 

Novacyt contact details:

Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw / George Kendrick

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / alex.shaw@fticonsulting.com / george.kendrick@fticonsulting.com 

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

 

UNICEF contact details:

Press contact:

Lorena Takahashi

+33 1 44 39 77 98

ltakahashi@unicef.fr 

 

Partnership contact:

Anne-Sophie Douillet

+33 1 73 01 17 21

adouillet@unicef.fr 

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information, please refer to the website: www.novacyt.com

 

About UNICEF

 

UNICEF promotes every child's rights and wellbeing. UNICEF works in 190 countries and territories with its partners to complete its mission, ensuring to reach the most vulnerable children, wherever they are. For more information about UNICEF and its work: www.unicef.fr 

 

 

UNICEF does not endorse any company, brand, product or service.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADKNBKCBKDNPK
Date   Source Headline
7th Feb 20209:00 amRNSPrice Monitoring Extension
7th Feb 20207:00 amRNSUpdate on novel coronavirus test
5th Feb 202011:05 amRNSSecond Price Monitoring Extn
5th Feb 202011:00 amRNSPrice Monitoring Extension
3rd Feb 20204:45 pmRNSLiquidity Agreement and Total Voting Rights
3rd Feb 202011:05 amRNSSecond Price Monitoring Extn
3rd Feb 202011:00 amRNSPrice Monitoring Extension
3rd Feb 20209:00 amRNSPrice Monitoring Extension
31st Jan 20206:15 pmRNSExercise of Warrants and Issue of Equity
31st Jan 20207:00 amRNSLaunch of novel coronavirus test
28th Jan 20207:00 amRNSFull Year Trading and Operational Update
17th Jan 20207:00 amRNSPrimerdesign partners with VGS Group in France
2nd Jan 202010:30 amRNSLiquidity Agreement Update and Total Voting Rights
27th Dec 20197:00 amRNSCompletion of NOVAprep® business sale
2nd Dec 20192:16 pmRNSLiquidity Agreement and Total Voting Rights
6th Nov 20197:00 amRNSNew term loan and termination of bond facility
1st Nov 20191:30 pmRNSLiquidity Agreement and Total Voting Rights
7th Oct 20197:00 amRNSMolecular respiratory panel ready for US market
3rd Oct 20194:15 pmRNSConversion of Loan Notes
1st Oct 20192:30 pmRNSLiquidity Agreement and Total Voting Rights
27th Sep 20193:23 pmRNSConversion of Loan Notes
26th Sep 20197:00 amRNSHalf Year Results
25th Sep 20193:46 pmRNSConversion of Loan Notes
23rd Sep 20191:00 pmRNSConversion of Loan Notes
18th Sep 20192:45 pmRNSConversion of Loan Notes
12th Sep 20193:00 pmRNSConversion of Loan Notes
11th Sep 20195:00 pmRNSConversion of Loan Notes
2nd Sep 20191:00 pmRNSLiquidity Agreement and Total Voting Rights
28th Aug 20195:00 pmRNSConversion of Loan Notes
27th Aug 20197:00 amRNSConversion of Loan Notes
12th Aug 20194:45 pmRNSConversion of Loan Notes
7th Aug 201911:00 amRNSConversion of Loan Notes
2nd Aug 20193:00 pmRNSConversion of Loan Notes
2nd Aug 20192:00 pmRNSChange of Adviser
1st Aug 201910:45 amRNSLiquidity Agreement and Total Voting Rights
30th Jul 20197:00 amRNSHalf-Year Trading Update
19th Jul 20198:12 amRNSReplacement Result of AGM
19th Jul 20197:03 amRNSResult of AGM
18th Jul 20193:30 pmRNSSale of Clinical Lab
18th Jul 201911:00 amRNSConversion of Loan Notes
16th Jul 20194:30 pmRNSConversion of Loan Notes
9th Jul 20191:00 pmRNSConversion of Loan Notes
1st Jul 201911:00 amRNSLiquidity Agreement and Total Voting Rights
28th Jun 20194:00 pmRNSConversion of Loan Notes
26th Jun 201910:30 amRNSAnnual General Meeting Update
24th Jun 20194:15 pmRNSConversion of Loan Notes
21st Jun 20194:18 pmRNSConversion of Loan Notes
20th Jun 20191:55 pmRNSAnnual General Meeting Update
20th Jun 20191:55 pmRNSConversion of Loan Notes
19th Jun 20197:00 amRNSConversion of Loan Notes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.